Asfotase alfa - Alexion Pharmaceuticals

Drug Profile

Asfotase alfa - Alexion Pharmaceuticals

Alternative Names: ALXN1215; Asfotase alpha; ENB-0040; Strensiq

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enobia Pharma
  • Developer Alexion Pharmaceuticals
  • Class Recombinant fusion proteins
  • Mechanism of Action Alkaline phosphatase stimulants; Esterase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypophosphatasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypophosphatasia
  • Preclinical Neurofibromatoses

Most Recent Events

  • 05 Jul 2017 NICE recommends asfotase alfa for the treatment of paediatric-onset hypophosphatasia
  • 01 Jun 2017 Alexion Pharma completes a phase IIa trial for Hypophosphatasia (paediatric-onset hyperphosphataemia) in USA and Germany (SC) (NCT02797821)
  • 15 May 2017 Adverse events data from a phase II trial in Hypophosphatasia released by Alexion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top